We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Notice for eltrombopag olamine (Novartis Pharmaceuticals Australia Pty Ltd)
Active ingredients
eltrombopag olamine
Date of review outcome
Lapse date
Type
Priority review
Dosage form(s)
Powder for oral suspension & Tablet, film-coated
Indication
Eltrombopag olamine in combination with standard immunosuppressive therapy (IST) for the first-line treatment of patients 2 years and older with severe aplastic anaemia (SAA).
Therapeutic area
Haematology